Abstract
SACT can cause reactivation of Hepatitis B virus (HBVr) in patients with prior HBV, with a risk of treatment interruption, liver failure or death. Ireland is classified as a low endemic area for HBV (Hepatitis B surface antigen (HbSAg) prevalence: 0.43%, Hepatitis B core antibody (antiHBc): 1.7%). ESMO recommends screening patients (pts) for HBV infection before starting SACT and prophylaxis as appropriate. In 2014, we found a 5.6% rate of prior infection in our pts. We aimed to reassess screening completeness, and to estimate the prevalence of HBV among our current pts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
